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produced by single protein molecules but
by aggregates of two or more molecules,
called multimeric lactalbumin (MAL).
Research on other cell types demonstrated
that the effect of MAL was selective-in
addition to tumor cells, lymphoid and
embryonic cells were also killed, while
mature normal cells of lung epithelium
and solid organs were left unharmed.
Moreover, the investigators noted that the
antitumor property of human milk is not
shared by bovine milk, which lacks the
ability to form aggregates ofthe protein.
Although animal experiments using
MAL are planned, Hakansson emphasizes
that MAL is not a cancer cure. "We don't
know anything about the in vivo effects of
the protein, or ifthis will work as an anti-
cancer drug," he said. In fact, Hakansson
feels the real significance ofhis observation
may be another line ofresearch it has stim-
ulated-the elucidation of the mechanism
bywhich MAL destroys tumor cells.
The researchers found that MAL
destroys tumor cells by inducing the
process ofapoptosis, the sequence ofgenet-
ically programmed steps by which cells self-
destruct. Apoptosis can occur naturally at
the end ofa cell's life or when a cell is dis-
eased and "sacrifices itself' to prevent the
spread ofdisease. In many diseases, howev-
er, the mechanism that initiates apoptosis
malfunctions. "In about 50% of tumors,
the cancer cells cannot undergo apoptosis,"
Hakansson observes. "The cells have inacti-
vated the pathway [for apoptosis], so they
live longer than they're supposed to. This is
a mechanism of cancer. The interesting
part ofthis study is that we can perhaps get
past this inactivation and still induce apop-
tosis in these cells," he said.
"This is a unique observation that could
have good potential in the design of new
antitumor agents," comments Kathryn
Rich, assistant professor of pathology and
ophthalmology at the University of
Southern California, whose research focuses
on apoptosis in neurons. One of the goals
of apoptosis research, Rich observes, is to
"use this normal physiological process as a
weapon against the cancer cell." Unraveling
the apoptotic pathways in cancer cells could
lead to design of antitumor agents that
would switch on apoptosis, thereby killing
cancer cells. An important finding of the
Swedish study, Rich adds, is the selectivity
of MAL's effects. "Most other external
agents tend to kill both normal and tumor
cells. Understanding why tumor cells are
sensitive [to MAL] and why normal gut
epithelial cells are resistant . . . could be
very promising."
According to Charles Isaacs, director of
the Laboratory ofProtein Chemistry at the
New York State Institute for Basic
Research, the new study is also important
because it suggests that breastfeeding plays
a previously unrecognized role in infant
development. He notes that while it has
long been known that human milk pro-
vides excellent nutrition and protection
against infection, a possible role in regulat-
ing cell growth has been hypothesized but
never demonstrated. "This study suggests
that yes, maybe some of the baby's cells
can be affected because there are com-
pounds in milk that induce apoptosis,"
Isaacs said. "It's possible that MAL has an
effect on cells in the baby's gastrointestinal
tract and also on the baby's own lympho-
cytes." Cautioning that further testing is
needed to see if the same effects can be
observed in vivo, Isaccs adds that the study
could stimulate research to find other sub-
stances in milk that regulate cell growth.
Why would milk contain a substance
that destroys tumor cells? The answer is
uncertain, but may lie in another ofMAL's
effects-it destroys not only tumor cells,
but immature cells as well. Hakansson
speculates that this selective cytotoxicity
may play a role in controlling populations
of maturing cells in the infant's gastroin-
testinal tract. Controlling the growth of
immature cells may, in fact, be the primary
function of MAL, and its effects on tumor
cells may be secondary. Hakansson notes,
"Cancer cells also have a very immature
cell phenotype, so [that may be the reason]
they are also affected." He adds, "It is not
strange that milk has effects other than just
nutrition. We see now that it has some
control over cell proliferation and cell
death."
TRI Troubles
In a move to prevent Republican lawmakers from weakening environmental laws
through amendments tacked onto the budget bills, President Clinton signed an execu-
tive order August 8 requiring companies that contract with the federal government to
report their releases oftoxic chemicals.
The impetus for the order was 1 of 18 amendments to the House appropriations
bill for the EPA. This rider would prohibit the EPA from requiring manufacturing
plants to report new data to the Toxics Release Inventory (TRI) of the 1986
Emergency Planning and Community Right-to-Know Act for any reason not already
in the law. The TRI contains emission reports of23,000 companies on 651 chemicals.
EPA Administrator Carol Browner said that the rider "essentially limits my ability to
guarantee that the people ofthis countrywill know about toxic chemicals in their com-
munities."
Although the executive order applies only to those firms doing business with the
federal government and would not exempt any company already reporting to the TRI,
it would effectively limit the EPA's proposed toxic use inventory-a system that would
include not only toxic emissions, but also toxic chemicals entering a plant's process.
Many industry groups, including chemical manufacturers, already question the effec-
tiveness ofthe TRI and are lobbying against the new inventory.
And there may be some evidence to support industry claims that TRI data do not
provide the most relevant information in terms of risk from chemical exposures.
Researcher Reid Lea and colleagues at the University ofNew Orleans developed a sys-
tem forweighing the riskoftoxic exposure to humans and the environment and used it
to analyze TRI data for Louisiana. They found that the amount ofa chemical released
into the environment does not necessarily correlate with the extent of the danger it
poses. In their paper, "Comparative Risk Analysis ofTRI Data as an Environmental
Indicator-A Louisiana Case Study," presented at the Air & Waste Management
Association's 88th Annual Meeting, the researchers wrote, "The traditional method of
analyzing the TRI data fails to address the true concerns about chemical emission to
the environment."
New Clues to Cell Death
Two groups of scientists have indepen-
dently identified an important trigger in
apoptosis, the complex sequence of events
that causes cells to self-destruct. The find-
ing raises the possibility of developing
drugs that could selectively induce or
inhibit apoptosis.
The trigger, a protease, or enzyme that
cleaves other proteins, was recently identi-
fied by Donald W. Nicholson at the
Merck Frosst Centre for Therapeutic
Research in Quebec, Muneesh Tewari at
the University of Michigan Medical
School, and their collaborators. In the July
6 issue of Nature, Nicholson and col-
leagues named the protease apopain. In the
June 2 issue of Cell, Tewari's group named
it "Yama" after the Hindu god of death.
The authors believe Yama/apopain is a cru-
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cial component of the mammalian cell-
death pathway. "It is something that we
suspect will be activated in a variety ofdif-
ferent instances ofapoptosis," Tewari said.
Apoptosis is a sequential, programmed
series ofsteps by which cells destroy them-
selves. Some scientists suggest that inappro-
priate apoptosis may be responsible for
damage seen in autoimmune disorders,
immune deficiencies, Alzheimer's, Hunt-
ington's and Parkinson's diseases, cancers,
stroke, andheartattack.
The recent discovery was made using
mammalian systems. It underscores the sim-
ilarities between apoptosis in the nematode
worm, Caenorhabditis elegant (which has
provided much ofour understanding about
apoptosis) and mammals. In the nematode,
apoptosis is controlled by sets of genes
including ced-3 and ced-9. Expression of
ced-3 is required for cell death to occur.
Expression of ced-9 blocks cell death. The
ced-9 gene is homologous to a set ofmam-
malian oncogenes.
Mammals also have a set ofgenes that
function like the nematode's ced-3 gene.
One such gene encodes an enzyme called
ICE, interleukin-1l converting enzyme.
ICE is implicated in some forms ofapopto-
sis but is not the trigger for all forms of
mammalian apoptosis. Scientists concluded
that a different, unidentified enzyme played
that role. Both Tewari's and Nicholson's
groups identified this enzyme as CPP32g, a
previously uncharacterized protein related
to ICE, which they named Yama/apopain.
As apoptosis begins, enzymes, induding one
called PARP [poly(ADP-ribose) poly-
merase], are cleaved into smaller fragments.
PARP maintains and repairs DNA. The
researchers used PARP cleavage to identify
Yama/apopain.
"I amsortofsurprised thatthisdiscovery
hasn't received more coverage in thescientif-
iclaypress. Itreallyis apivotalfinding," said
Tewari's co-author Vishva M. Dixit ofthe
University ofMichigan Medical School. "It
allows for the first time a toe in the door of
mammalian cell death. We can enlarge on
the knowledge and identify the other com-
ponents. I think the entire story, the essen-
tial components ofthe pathway, will proba-
blyfall inplace the nextcoupleofyears."
Gloria Preston, an apoptosis researcher
at the NIEHS, notes that this is an impor-
tant finding because proteolytic cleavage
does appear to play arole in apoptosis. "Ap-
parently, other proteases exist that have
some similarity to Yama/apopain, and
whether this particular protease is pivotal to
the process is not dear. At this time it is dif-
ficult to determine what cleavage events are
essential and what ones are merely part of
the degradation process."
Yama. University of Michigan researchers named
the new-found apoptosis enzyme after the Hindu
god ofdeath.
Yama/apopain does appear to be the key
protease in the apoptosis studied in the
mammalian osteosarcoma cells described by
Nicholson et al., according to Shai Shahan,
who studies apoptosis in nematodes at
MIT. But since Yama/apopain is part of a
family of proteases, it is possible there is
redundancy. More than one protease might
be responsible for triggering cell death in a
given cell. Also, one protease might be
responsible for activating cell death in a
given tissue and another protease of the
same class will activate it in yet another tis-
sue, Shahan said.
That would please pharmaceutical com-
panies. The question from a pharmaceutical
point ofview is whether or not there are
certain proteases that are present in only
certain cells. "I guess the ideal thing would
be if in a neurodegenerative disease there
were an ICE homologue or close relative
that caused cell death. Ifone could identify
aspecific inhibitor, wewould be able to pre-
vent cell death," said Douglas K. Miller,
senior investigator at the Merck Research
Laboratories in NewJersey, and a co-author
ofthe Cellpaper. In applying the finding to
cancer therapy, however, it would be neces-
sary to induce, not inhibit, apoptosis under
controlled conditions.
While Dixit and colleagues are now
concentrating on identifying the enzyme
that activates Yama, the Merck researchers
are concentrating on characterizing the five
other mammalian homologues of ICE.
They will then look at them to see ifthey
are associated atallwith disease, Millersaid.
Consequences of Climate
Change
Intense summer heat waves could kill thou-
sands more people each year in New York,
St. Louis, andother U.S. cities, epidemics of
infectious diseases could continue sweeping
into temperate climates from the tropics,
and numbers ofskin cancers will probably
rise in mid-latitude regions of North
America, Europe, and Australia, all during
the next century. These impacts of climate
change were predicted by experts at the
Conference on Human Health and Global
Climate Change, September 11-12, at the
National Academy of Sciences in
Washington, DC.
Until recently, scientists and policymak-
ers hadprimarilyfocused on howthe earth's
physical systems would be affected byglobal
warming, examining the potential for
increased sea level rises and bigger hurri-
canes. But the Intergovernmental Panel on
Climate Change, in a forthcoming update
of its 1990 study, will for the first time
include a chapter on the possible human
health effects of climate change. In turn,
Vice President Al Gore asked the Office of
Science and Technology Policy and the
Council on Environmental Quality to orga-
nize a conference on this theme. Co-spon-
sored by the National Science and
Technology Council and the Institute of
Medicine, the conference gathered a diverse
group of experts from academia, govern-
ment, and nongovernmental organizations.
Conference participants discussed how di-
mate change might damage human health,
then made recommendations for improving
global health surveillance systems, research,
education ofhealth professionals, and inter-
national cooperation.
In industrialized nations, the greatest
impacts ofclimate change probably will be
experienced through heat waves. Global
warming of 1-30C would probably
increase the frequency ofintensely hot days
in temperate regions, resulting in several
thousand extra deaths annually due to heat
stress in the United States, said Laurence S.
Kalkstein of the Center for Climatic
Research at the University of Delaware.
More than 500 Chicagoans died during a
July 1995 heat wave, a type ofdisaster that
could occur more often in the future.
"Living in heat-trapping brick tenements
with black-tar roofs, many poor, elderly, or
frail residents ofNew York, Chicago, and
other cities will be unable to adjust to a
warmingclimate," said Kalkstein.
Faced with hotter summers, those who
can afford air conditioning will use it more
frequently, resulting in more air pollution,
predicted Joel Schwartz, epidemiologist at
the Harvard University School of Public
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